宫颈癌紫杉醇化疗耐药机制的研究进展

Research progress on the mechanism of drug resistance to paclitaxel chemotherapy in cervical cancer

宫颈癌是女性生殖系统最常见的恶性肿瘤之一,尽管在早期筛查和预防方面取得了突破性进展,但在发展中国家宫颈癌的发病率和死亡率仍呈上升趋势。紫杉醇属于宫颈癌治疗的一线化疗药物,由于其极易产生化疗耐药,严重影响患者治疗效果及预后,因此了解其化疗耐药的分子机制具有重要意义。本文对宫颈癌紫杉醇化疗耐药机制的研究进展做一综述,以期为克服宫颈癌的化疗耐药提供新的思路。

Cervical cancer is one of the most common malignant tumors of the female reproductive system.Although this is despite breakthroughs in early screening and prevention,the incidence and mortality rates of cervical cancer are still on the rise in developing countries.Paclitaxel is a first-line chemotherapy drug for the treatment of cervical cancer,and because it is easy to produce chemotherapy resistance,it seriously affects the therapeutic effect and prognosis of patients.Therefore,it is of great significance to understand the molecular mechanism of chemotherapy resistance.In this paper,the research progress on the mechanism of chemotherapy resistance of paclitaxel in cervical cancer was reviewed,in order to provide new ideas for overcoming chemotherapy resistance of cervical cancer.